# Disease Registry on Patients with Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

**First published:** 07/06/2022

**Last updated:** 02/07/2024





# Administrative details

**Study description** 

| EU PAS number    |  |
|------------------|--|
| EUPAS47602       |  |
| Study ID         |  |
| -                |  |
| 47603            |  |
| DARWIN EU® study |  |
| No               |  |
| Study countries  |  |
| Germany          |  |
| United States    |  |
|                  |  |

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants, demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy. This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

#### **Study status**

Ongoing

#### Research institutions and networks

#### **Institutions**

# Merck Healthcare KGaA Germany First published: 26/02/2024 Last updated: 26/02/2024 Institution

### Contact details

#### **Study institution contact**

Communication Center Merck KGaA service@merckgroup.com

**Study contact** 

service@merckgroup.com

#### **Primary lead investigator**

Communication Center Merck KGaA

**Primary lead investigator** 

# Study timelines

#### Date when funding contract was signed

Planned: 30/06/2022

#### Study start date

Planned: 30/06/2022 Actual: 04/03/2022

#### Date of final study report

Planned: 31/03/2027

# Sources of funding

Pharmaceutical company and other private sector

# More details on funding

Merck KGaA

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

Study type list

#### Study type:

Non-interventional study

#### Scope of the study:

Disease epidemiology

#### Main study objective:

It will aim to collect prospectively (with longitudinal follow-up) high-quality, standardized, & contemporaneous data to capture changes in the NSCLC treatment landscape & outcomes over time. The registry would capture data on patient and clinical characteristics treatment patterns, and effectiveness and

safety outcomes for advanced NSCLC METex14 patients treated with systemic therapy.

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

#### Medical condition to be studied

Non-small cell lung cancer

#### Additional medical condition(s)

METex14 Skipping Alterations

# Population studied

#### **Age groups**

- Preterm newborn infants (0 27 days)
- Term newborn infants (0 27 days)
- Infants and toddlers (28 days 23 months)
- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)</li>
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)

- Adults (75 to < 85 years)
- Adults (85 years and over)

#### **Special population of interest**

Hepatic impaired

Immunocompromised

Pregnant women

Renal impaired

#### **Estimated number of subjects**

700

# Study design details

#### **Outcomes**

Best Overall Response (BOR), Overall Survival (OS), Number of Participants with Adverse Events (AEs), and Number of Participants with Adverse Reactions (ARs)

#### Data analysis plan

Not applicable

# Data management

#### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency

but are no longer maintained.

#### Data sources

#### Data sources (types)

Disease registry

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

#### **Check logical consistency**

Unknown

# Data characterisation

#### **Data characterisation conducted**